ATE209908T1 - RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN - Google Patents

RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN

Info

Publication number
ATE209908T1
ATE209908T1 AT92914539T AT92914539T ATE209908T1 AT E209908 T1 ATE209908 T1 AT E209908T1 AT 92914539 T AT92914539 T AT 92914539T AT 92914539 T AT92914539 T AT 92914539T AT E209908 T1 ATE209908 T1 AT E209908T1
Authority
AT
Austria
Prior art keywords
disorders
derivatives
pbn
ischemia
spin
Prior art date
Application number
AT92914539T
Other languages
English (en)
Inventor
John M Carney
Robert A Floyd
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE209908T1 publication Critical patent/ATE209908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92914539T 1991-06-18 1992-06-18 RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN ATE209908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71695291A 1991-06-18 1991-06-18
PCT/US1992/005194 WO1992022290A1 (en) 1991-06-18 1992-06-18 Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins

Publications (1)

Publication Number Publication Date
ATE209908T1 true ATE209908T1 (de) 2001-12-15

Family

ID=24880110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92914539T ATE209908T1 (de) 1991-06-18 1992-06-18 RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN

Country Status (5)

Country Link
EP (1) EP0590072B1 (de)
AT (1) ATE209908T1 (de)
CA (1) CA2111836C (de)
DE (1) DE69232263T2 (de)
WO (1) WO1992022290A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
JP3167763B2 (ja) 1991-11-07 2001-05-21 株式会社ユニエ 創傷治癒促進剤
US5455272A (en) * 1993-10-22 1995-10-03 Oklahoma Medical Research Foundation Spin trap nitronyl hindered phenols
US5405967A (en) * 1993-10-22 1995-04-11 Oklahoma Medical Research Foundation Spin-trap molecules 2-trifluoromethyl- of 5,5-dimethyl-1-dyrroline-N-oxide
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
DE9408805U1 (de) * 1994-05-30 1994-09-01 Baur, Albert, 86845 Großaitingen Lautsprecher, insbesondere in Säulenform
JPH0870889A (ja) * 1994-09-02 1996-03-19 Tokyo Jiyoshi Ika Univ 臓器障害誘導因子の検出方法
JPH11512427A (ja) * 1995-09-11 1999-10-26 ヘキスト・マリオン・ルセル・インコーポレイテツド 環状ニトロンおよびこれらを含有する医薬組成物
NZ332561A (en) * 1996-04-23 2001-01-26 Centaur Pharmaceuticals Inc Compositions comprising a nitrone compound for use in treating ocular inflammation
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
KR20000067915A (ko) * 1996-07-19 2000-11-25 센토르 파마슈티칼스, 인크. 푸란 니트론 화합물
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
WO1999036415A1 (en) * 1998-01-16 1999-07-22 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
WO1999036420A1 (en) * 1998-01-16 1999-07-22 Centaur Pharmaceuticals, Inc. Thiophene nitrone compounds
EP1061916A2 (de) * 1998-03-13 2000-12-27 Centaur Pharmaceuticals, Inc. Verwendung von notronverbindungen zur hemmung von gefässneubildung
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
ATE271384T1 (de) * 1998-05-19 2004-08-15 Renovis Inc Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
EP1077696A1 (de) * 1998-05-19 2001-02-28 Centaur Pharmaceuticals, Inc. Furan-nitrone therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
AU4184499A (en) 1998-05-19 1999-12-06 Renovis, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
RU2225392C2 (ru) * 1998-06-24 2004-03-10 Реновис, Инк. Альфа-арил-N-алкилнитроны, фармацевтические композиции (варианты), способ ингибирования нейродегенеративных заболеваний, способ лечения и способы профилактики (варианты)
FR2780404B1 (fr) * 1998-06-26 2001-04-13 Adir Nouveaux derives de nitrone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002520386A (ja) 1998-07-17 2002-07-09 セントアー ファーマシューティカルズ インコーポレイテッド 炎症を処置するためのα−（２−ヒドロキシフェニル）ニトロン化合物、α−（２−ヒドロキシフェニル）ニトロン化合物を含む薬学的組成物およびそれらの使用
AU1917301A (en) * 1999-11-18 2001-05-30 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics and methods for treating inflammatory bowel disease
US6835754B2 (en) 2001-01-08 2004-12-28 Renovis, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20050192281A1 (en) * 2003-10-14 2005-09-01 Kelly Michael G. Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders
WO2006066987A1 (en) * 2004-12-22 2006-06-29 Ciba Specialty Chemicals Holding Inc. Anti-radical agents
ES2349415T3 (es) * 2004-12-22 2011-01-03 Basf Se Agentes antiradicales.
CN101346136A (zh) * 2005-10-24 2009-01-14 西巴控股公司 可氧化剂的保护
FR2902097A1 (fr) * 2006-06-13 2007-12-14 Univ Joseph Fourier Etablissem Nouveau procede de preparation de nitrones et de n-hydroxylamines comportant au moins un groupe hydroxyle, et produits tels qu'obtenus
AU2007277193B2 (en) 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
US8227517B2 (en) 2008-02-12 2012-07-24 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
WO2015134688A1 (en) * 2014-03-07 2015-09-11 Dow Global Technologies Llc Nitrone compounds and their use in personal care
EP3142752B1 (de) * 2014-05-12 2018-06-20 Dow Global Technologies Llc Nitron verbindungen und ihre verwendung in der körperpflege
JP6734204B2 (ja) 2014-06-30 2020-08-05 ダウ グローバル テクノロジーズ エルエルシー ポリマーニトロン及びパーソナルケアにおけるそれらの使用
CN107427430B (zh) 2015-03-20 2020-12-04 陶氏环球技术有限责任公司 不饱和脂肪氧化的硝酮抑制
BR112017018503B1 (pt) 2015-03-20 2021-08-24 Dow Global Technologies Llc Composição de cuidados pessoais

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
WO1988005653A1 (en) * 1987-01-28 1988-08-11 Proctor Peter H Topical composition for stimulating hair growth with stable free radicals
WO1991005552A1 (en) * 1989-10-17 1991-05-02 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration

Also Published As

Publication number Publication date
AU672364B2 (en) 1996-10-03
CA2111836C (en) 2006-08-29
DE69232263D1 (de) 2002-01-17
WO1992022290A1 (en) 1992-12-23
AU2261492A (en) 1993-01-12
EP0590072A1 (de) 1994-04-06
DE69232263T2 (de) 2003-06-18
EP0590072B1 (de) 2001-12-05
CA2111836A1 (en) 1992-12-23

Similar Documents

Publication Publication Date Title
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
BG101118A (en) Therapeutical compounds
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2&#39;- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE58904722D1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
NO801387L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive morfantridin-derivater
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE69325512D1 (de) Verwendung von remacemid zur behandlung des morbus parkinson
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR900017599A (ko) 종양 치료용 약학 조성물

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties